IMVT
Immunovant Inc
NASDAQ: IMVT · HEALTHCARE · BIOTECHNOLOGY
$26.95
-0.15% today
Updated 2026-04-29
Market cap
$5.49B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.67
Dividend yield
—
52W range
$13 – $30
Volume
1.4M
Immunovant Inc (IMVT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | $21000.00 | $998000.00 | $1.23M | $1.32M | $231000.00 | $377000.00 |
| Gross profit | — | — | — | $-21000.00 | $-998000.00 | $-1.23M | $-1.32M | $-231000.00 | $-377000.00 |
| Gross margin | — | — | — | — | — | — | — | — | — |
| R&D | $135.26M | — | $25.73M | $47.93M | $68.60M | $101.81M | $160.26M | $212.93M | $360.92M |
| SG&A | $1.48M | — | $2.69M | $18.15M | $39.51M | $54.23M | $48.02M | $57.28M | $77.23M |
| Operating income | $-136.74M | $-450.00 | $-450.00 | $-59.68M | $-108.12M | $-156.03M | $-208.28M | $-270.21M | $-438.15M |
| Operating margin | — | — | — | — | — | — | — | — | — |
| EBITDA | — | — | $-28415.00 | $-65.64M | $-108.05M | $-155.91M | $-208.08M | $-269.98M | $-437.77M |
| EBITDA margin | — | — | — | — | — | — | — | — | — |
| EBIT | $-136.74M | — | $-450.00 | $-65.67M | $-108.12M | $-156.03M | $-208.28M | $-270.21M | $-438.15M |
| Interest expense | $0.00 | $0.00 | $0.00 | $625000.00 | $0.00 | $655000.00 | $12.48M | $49.90M | — |
| Income tax | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-136.74M | $-450.00 | $-450.00 | $-66.39M | $-107.43M | $-156.73M | $-210.96M | $-259.34M | $-413.84M |
| Net income growth (YoY) | — | +100.0% | +0.0% | -14752788.9% | -61.8% | -45.9% | -34.6% | -22.9% | -59.6% |
| Profit margin | — | — | — | — | — | — | — | — | — |